Effects of Tetrakis (nicotinoyloxymethyl) Cyclohexanol (Nicomol) and Ethyl Chlorophenoxyisobutyrate (Clofibrate) on Lipid Metabolism and Drug-Metabolizing and other Enzymes

• Published in: Kanzo Vol. 15; no. 4; pp. 236 - 246
• Main Authors: AKAMATSU, Koichi, SHIMAMURA, Junnosuke, TAKESUE, Atsushi, TAKETA, Kazuhisa
• Format: Journal Article
• Language: English; Japanese
• Published: The Japan Society of Hepatology 1974
• Subjects: Clofibrate; Nicomol
• ISSN: 0451-4203; 1881-3593
• DOI: 10.2957/kanzo.15.236

A combined administration of tetrakis (nicotinoyloxymethyl) cyclohexanol (Nicomol) and ethyl α-(p-chlorophenoxy)-isobutyrate (CPIB) to a case of familial type II hyperlipoproteinemia gave results suggestive of an additive lipid-lowering effect of these two compounds. In an attempt to prove this results, effects of the two compounds on metabolite and enzyme levels were studied with rats. Liver weight and contents of liver protein and total phospholipid were increased by a factor of about 1.5 and liver glycogen content was significantly decreased in CPIB treated rats. In Nicomol-fed rats, these changes were not observed. Serum triglyceride concentration decreased with each compound, although the additive lipid-lowering effect of the two compounds was not observed with rats. Activities of microsomal drug-metabolizing enzymes tended to increase slightly with Nicomol and significantly increased with CPIB. Glucokinase, hexokinase and glucose 6-phosphate dehydrogenase activities were not significantly changed in livers of Nicomol-fed rats. In rats fed CPIB or both compounds, these enzyme activities changed significantly without showing liver cell injury.